AGREEMENT FOR AMENDMENT TO SERIES A AND SERIES B WARRANTSAmendment Agreement • December 12th, 2017 • Repros Therapeutics Inc. • Biological products, (no disgnostic substances) • New York
THIS AGREEMENT FOR AMENDMENT TO SERIES A AND SERIES B WARRANTS (this “Amendment Agreement”) is dated as of December 11, 2017, by and between Repros Therapeutics, Inc., a Delaware corporation (the “Company”) and the investor listed in the signature page attached hereto (the “Holder”).
AGREEMENT FOR AMENDMENT TO SERIES A AND SERIES B WARRANTSAgreement • December 12th, 2017 • Repros Therapeutics Inc. • Biological products, (no disgnostic substances) • New York
THIS AGREEMENT FOR AMENDMENT TO SERIES A AND SERIES B WARRANTS (this “Amendment Agreement”) is dated as of December 11, 2017, by and between Repros Therapeutics, Inc., a Delaware corporation (the “Company”) and the investor listed in the signature page attached hereto (the “Holder”).
AGREEMENT AND PLAN OF MERGER by and among ALLERGAN SALES, LLC, CELESTIAL MERGER SUB, INC. and REPROS THERAPEUTICS INC. dated as of December 11, 2017Agreement and Plan of Merger • December 12th, 2017 • Repros Therapeutics Inc. • Biological products, (no disgnostic substances) • Delaware
This AGREEMENT AND PLAN OF MERGER (this “Agreement”), dated December 11, 2017, is by and among ALLERGAN SALES, LLC, a Delaware limited liability company (“Parent”), CELESTIAL MERGER SUB, INC., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), and REPROS THERAPEUTICS INC., a Delaware corporation (the “Company”). All capitalized terms used in this Agreement shall have the meanings ascribed to such terms in Section 10.5 or as otherwise defined elsewhere in this Agreement unless the context clearly provides otherwise. Parent, Merger Sub and the Company are each sometimes referred to as a “Party” and collectively as the “Parties.”
ESCROW AGREEMENTEscrow Agreement • December 12th, 2017 • Repros Therapeutics Inc. • Biological products, (no disgnostic substances) • Delaware
THIS ESCROW AGREEMENT (as the same may be amended or modified from time to time pursuant hereto, this “Agreement”) is entered into as of December [ ], 2017, by and among Allergan Sales, LLC (“Parent”), Repros Therapeutics Inc. (the “Company”, and together with Parent, sometimes referred to individually as “Party” and collectively as the “Parties”), and JPMorgan Chase Bank, N.A. (“Escrow Agent”).
